---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-056101"
form_type: "8-K"
ticker: "BBWI"
cik: "0000701985"
company_name: "Bath & Body Works, Inc."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-26T00:05:49.544445+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CEO Andrew Meslow to depart May 12; receives $7M severance, extended non-compete

## Summary
- CEO Andrew M. Meslow resigns effective May 12, 2022 due to health reasons.
- Severance: $7 million cash over 24 months plus health coverage for 24 months.
- Non-compete extended to 24 months globally; unvested equity forfeited (86k options, 123k RSUs, 1.3M PSUs).
- Transition agreement unanimously approved by Board; Meslow agrees to cooperate and release claims.

## SEC filing metadata
- accession: 0001104659-22-056101
- form_type: 8-K
- ticker: BBWI
- cik: 0000701985
- company_name: Bath & Body Works, Inc.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/701985/000110465922056101/0001104659-22-056101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/701985/000110465922056101/tm228755d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-056101
- JSON: https://secwatch.observer/filing/0001104659-22-056101.json
- Plain text: https://secwatch.observer/filing/0001104659-22-056101.txt

## Key facts
- Executive change
  Andrew M. Meslow departed as Chief Executive Officer at Bath & Body Works, Inc..
  - Action: departed
  - Role: Chief Executive Officer
  source text: On May 4, 2022, Andrew M. Meslow, Chief Executive Officer of Bath & Body Works, Inc. (the “Company”) and a member of the Company’s Board of Directors (the “Board”), entered into a Transition and General Release Agreement (the “Transition and Release Agreement”) with the Company, in anticipation of his previously announced departure due to health reasons effective on May 12, 2022 (the “Separation Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/701985/000110465922056101/0001104659-22-056101-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.